The human immunodeficiency virus (HIV) therapy market is dynamic and growing. With the launches of many effective antiretroviral therapies (ART), such as Gilead’s Biktarvy and ViiV’s Dovato, Juluca, and Cabenuva (long-acting once-monthly injection), safety and tolerability have become the key differentiating attributes among ART regimens. For the majority of patients, current ARTs such as single-tablet regimens (STRs) have achieved maximal antiretroviral efficacy and tolerability, changing HIV infection from a fatal disease to a tolerable chronic condition. Despite this achievement, adherence to regular oral medicine consumption remains a problem; however, the recent label expansion of Cabenuva, a novel medication delivery strategy, is poised to transform the treatment landscape, reducing the once-daily pill burden to only six intramuscular injections each year. This report focuses on the current treatment and anticipated use of HIV treatment regimens, including recently approved ARTs such as Trogarzo and Rukobia, for heavily treatment-experienced patients with multidrug-resistant HIV-1 infection, by capturing the patient market share data, current prescribing trends, and anticipated changes in prescribing and treatment behavior. The key prescribing drivers and barriers and sales force performance for key brands will be evaluated. This content will quantitatively explore the current treatment of HIV as marketed ARTs and novel agents advance in the pipeline.
Markets covered: United States
Key companies: Gilead Sciences, ViiV Healthcare, Janssen, Boehringer Ingelheim, Merck & Co.
Key drugs: Biktarvy, Dovato, Juluca, Cabenuva, Genvoya
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.